A Multicenter, Long-Term, Open-label, Study to Assess the Safety and Tolerability of Aripiprazole as an Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder.
Latest Information Update: 08 Oct 2020
At a glance
- Drugs Aripiprazole (Primary) ; Antidepressants
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 15 Sep 2020 Results (n=1547) presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 03 May 2008 Results were presented at the 161st Annual Meeting of the American Psychiatric Association.
- 20 Dec 2007 Status changed from in progress to completed.